enGene (NASDAQ:ENGN) Research Coverage Started at Guggenheim

Guggenheim began coverage on shares of enGene (NASDAQ:ENGN) in a report released on Monday, MarketBeat reports. The firm issued a buy rating and a $34.00 price objective on the stock.

Several other equities research analysts also recently commented on ENGN. SVB Leerink assumed coverage on shares of enGene in a report on Tuesday, February 20th. They set an outperform rating and a $31.00 price objective on the stock. Leerink Partnrs restated an outperform rating on shares of enGene in a research note on Tuesday, February 20th. UBS Group initiated coverage on shares of enGene in a research note on Thursday, March 28th. They issued a buy rating and a $37.00 price objective for the company. Finally, Morgan Stanley started coverage on shares of enGene in a report on Friday, March 8th. They set an overweight rating and a $40.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, enGene currently has a consensus rating of Buy and a consensus price target of $35.50.

enGene Stock Performance

Shares of ENGN opened at $15.74 on Monday. enGene has a 1 year low of $6.69 and a 1 year high of $43.00. The company has a fifty day moving average price of $15.71.

Hedge Funds Weigh In On enGene

A number of large investors have recently modified their holdings of ENGN. Vivo Capital LLC purchased a new stake in enGene in the 4th quarter worth approximately $6,264,000. Goldman Sachs Group Inc. purchased a new stake in shares of enGene in the fourth quarter worth $346,000. Royal Bank of Canada bought a new stake in enGene during the fourth quarter valued at $349,000. Citadel Advisors LLC purchased a new position in enGene during the fourth quarter worth about $185,000. Finally, BVF Inc. IL bought a new position in enGene in the 4th quarter worth about $20,777,000. 64.16% of the stock is currently owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.